BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%
Go back to BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 10.09 -0.08 (0.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.17 | 52 Week High | $10.98 | |||
| Open | $10.15 | 52 Week Low | $1.63 | |||
| Day High | $10.22 | P/E | N/A | |||
| Day Low | $9.94 | EPS | $-0.68 | |||
| Volume | 1,973,758 | |||||
